Glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) are an important class of drugs with a well-established efficacy and safety profile in patients with type 2 diabetes mellitus. Agents in this class are derived from either exendin-4 (a compound present in Gila monster venom) or modifications of human GLP-1 active fragment.
tered by subcutaneous injection. [3] [4] [5] [6] [7] [8] [9] In general, GLP-1 RAs can be categorised as either "short-acting"
(having short-lived receptor activation, eg, exenatide twice daily and lixisenatide) or "long-acting" (producing continuous activation of the GLP-1 receptor at recommended dosages, eg, albiglutide, dulaglutide, exenatide once weekly, liraglutide, and semaglutide). 10 As a class, GLP-1 RAs demonstrate good glycaemic efficacy.
Although a detailed account of their efficacy profiles is beyond the scope of this review, 67 The efficacy of various GLP-1 RAs was sustained for at least 2 to 5 years both in clinical trials 18, 31, 68, 69 and in open-label extension observations. [70] [71] [72] Direct comparative trials and a metaanalysis demonstrated that the long-acting agents were associated with significantly greater reductions in HbA 1c than short-acting agents. 36, 45, 46, 57, 73, 74 Differences have also been reported between the different weekly GLP-1 RAs in terms of the amplitude of their effects on HbA 1c (Table 1) . For example, among long-acting GLP-1
RAs administered once weekly, a network meta-analysis (primarily designed to assess cardiometabolic outcomes) showed that dulaglutide 1.5 mg and exenatide once weekly were associated with the largest and albiglutide with the smallest mean reductions in HbA 1c
values (−1.3% to −1.4% and −1.0% vs placebo, respectively). 75 Corresponding values reported in key clinical trials range from −0.55% to −0.83% for albiglutide 30 to 50 mg, −0.71% to −1.64% for dulaglutide 0.75 to 1.5 mg, −1.28% to −1.9% for exenatide once weekly, −0.74% to −1.5% for liraglutide 1.2 to 1.8 mg, and −1.1% to −1.8% for semaglutide 0.5 to 1 mg (Table 1) . For short-acting agents, HbA 1c
reductions in clinical trials range from −0.4% to −1.74% for exenatide twice daily and from −0.7% to −0.9% for lixisenatide (Table 1) .
Differences in the abilities of short-and long-acting GLP-1 RAs to reduce HbA 1c levels have been associated with their differing halflives and mechanisms of action, resulting in varying effects on GLP-1 receptor activation, gastric emptying, and postprandial glucose. 10 Pharmacokinetic differences between GLP-1 RAs, and the implications of these for the biological effects associated with individual GLP-1
RAs, are discussed in more detail in Sections 3.3 and 3.4.
Glucagon-like peptide-1 RAs are also characterised by their ability to reduce body weight in patients with T2DM. Reductions in body weight of 1.21 to 4.6 kg from baseline have been reported in patients treated with GLP-1 RAs when added to metformin. 11, 18, 19, 23, 31, 37, 42, 47, 51, 59 Changes in body weight for long-acting agents (some administered in combination with other OADs) in key clinical trials ranged from +0.28 to −1.21 kg for albiglutide 30 to 50 mg, +0.20 to −3.03 kg for dulaglutide 0.75 to 1.5 mg, −2.0 to −3.7 kg for exenatide once weekly, +0.3 to −3.38 kg for liraglutide 1.2 to 1.8 mg once daily, and −3.47 to −6.5 kg for semaglutide 0.5 to 1 mg (Table 1 ). For short-acting agents, changes in body weight were −0.9 to −2.8 kg for exenatide twice daily and +0.30 to −2.96 kg for lixisenatide once daily (Table 1 ). In the meta-analysis of long-acting once-weekly agents reported by Zaccardi et al (published prior to the approval of semaglutide), 75 dulaglutide 1.5 mg and exenatide once weekly were associated with the largest reductions in body weight versus placebo (−0.8 kg), whereas albiglutide 30 to 50 mg had no effect.
Although the exact mechanisms responsible for the effects of the GLP-1 RAs on body weight reduction are not yet fully understood, both central and peripheral mechanisms are thought to play a part in activating receptors in the central nervous system associated with weight loss. [76] [77] [78] [79] [80] Indeed, GLP-1 RAs are believed to reduce body weight through reduced gastrointestinal motility and the promotion of feelings of satiety via the activation of GLP-1 receptors in various regions of the brain. 80 Most drugs that are available to treat obesity are small molecules that are able to cross the blood-brain barrier (BBB), affecting central networks. 76 Nevertheless, large GLP-1 RA fusion proteins have demonstrated clear weight reduction effects in patients with T2DM, although albiglutide is less effective in this regard than the other GLP-1 RAs (Table 1) . 79 One suggested reason for this is that as a large fusion protein (for more information see Section 3.1), albiglutide is too large to cross the BBB and may, as a consequence, have fewer central effects than smaller GLP-1 RA molecules. 10 Alternatively, preclinical data indicate that certain large-molecular-weight long-acting GLP-1 RAs administered peripherally may be able to access specific centrally located brain areas protected by the BBB that govern appetite regulation, [76] [77] [78] suggesting that both central and peripheral mechanisms play a part in activating receptors in central nervous system centres.
Other reported benefits of GLP-1 RAs in patients with T2DM
include reductions in systolic and diastolic blood pressure and improvements in lipid profiles. 14, 15, 32, 36, 37, 42, [45] [46] [47] [48] [49] 52, 53, [58] [59] [60] [61] [62] [63] 65, 71, 81 Modest improvements in nonclinical parameters such as markers of beta-cell function have also been reported. 14, 16, 19, 36, 37, 48, [50] [51] [52] [53] [54] 58, 60, 64, 65, 70, 71, [82] [83] [84] In general, the main adverse events related to GLP-1 RAs are gastrointestinal in nature, although onset, duration, and frequency vary between individual agents. These are discussed in more detail later in this review.
Few differences have been identified between the GLP-1 RAs with respect to overall safety, but an in-depth assessment is beyond the scope of this review. In brief, although most GLP-1 RAs have Liraglutide in combination with glimepiride. 54 been shown to increase the heart rate to varying degrees, 15, 28, [30] [31] [32] [36] [37] [38] 42, 43, 46, 48, 50, 52, 54, 55, 58, 59, 61, 72, 81, 82, 85 Thyroid C-cell cancer has been reported in rodent studies with exenatide, 3,4 dulaglutide, 7 liraglutide, 6 lixisenatide, 5 and semaglutide, 9 and the US prescribing information for long-acting GLP-1 RAs includes a warning regarding the risk of thyroid C-cell tumours. [101] [102] [103] [104] [105] Studies characterising specific features of individual GLP-1 RAs were also included.
Semaglutide had not been approved for the treatment of T2DM
by the time this review was submitted for publication and so was not included as a term in the literature search; inclusion of SUSTAIN programme data were specifically requested during the review procedure. Exenatide shows 53% amino acid sequence homology with human GLP-1 and binds to the human GLP-1 receptor with an affinity equivalent to that of human GLP-1 ( Table 2) . 124 Amino acid modifications to the parent molecule make exenatide more resistant to cleavage by DPP-4 and prolong its half-life relative to human GLP-1. The original formulation of exenatide requires twice-daily dosing, whereas a longer-acting poly-microsphere preparation that allows continuous release of drug from a subcutaneous depot can be administered once weekly.
Lixisenatide has a similar homology to that of exenatide but has been modified to allow it to better withstand physiological degradation by DPP-4 ( Table 2 ). The binding affinity of lixisenatide to the GLP-1 receptor is about 4-fold greater than that of human GLP-1.
125
Despite lixisenatide having a terminal half-life of about 3 hours, 117 initial dose-finding studies found once-or twice-daily lixisenatide 20 mcg resulted in only small differences in HbA 1c reduction. 10, 126 Hence, the drug can be administered once daily. The degree of homology of lixisenatide to human GLP-1 is similar to that of exenatide. Albiglutide is a recombinant fusion protein with >90% homology to human GLP-1 RA. Albiglutide comprises 2 tandem copies of modified human GLP-1 genetically fused in tandem to human albumin 8, 102 ( Table 2) , which prolongs the half-life of albiglutide relative to human GLP-1, allowing once-weekly dosing.
102
Dulaglutide has 90% homology with human GLP-1 RA and is covalently linked to a modified human IgG4-Fc heavy chain by a small peptide linker. 103 The recombinant fusion to a protein carrier reduces the rate of clearance of the drug and limits its potential renal excretion, 119 thus increasing the plasma half-life and allowing once-weekly dosing (Table 2 ).
127
Liraglutide shows 97% homology to human GLP-1. 104 Selfassociation of liraglutide, which delays skin absorption, and a fatty acid side chain allowing binding to circulating albumin increase the duration of action of liraglutide (Table 2) , prolonging its half-life relative to human GLP-1 and allowing once-daily dosing.
104
Semaglutide has 94% homology with human GLP-1 RA and is linked via a hydrophilic spacer and a fatty acid side chain to albumin (Table 2) , which extends its half-life relative to human GLP-1, allowing once-weekly dosing. 105 
| Pharmacokinetics
The half-lives of GLP-1 RAs range from 2 to 3 hours for short-acting agents and from 13 hours to approximately 7 days for long-acting agents ( 
| Duration of action and profile of biological effects
The differences in duration of action and rapidity of onset of action between short-and long-acting agents can influence the biological effects of GLP-1 RAs on fasting and postprandial glucose levels (Tables 2 and 3 ).
| Short-acting GLP-1 RAs
Short-acting GLP-1 RAs are usually administered prior to food, typically before breakfast and dinner (exenatide twice daily) or breakfast (lixisenatide once daily). The short half-lives of these agents mean they activate the GLP-1 receptor for only~6 hours, after which plasma drug concentrations decline to baseline levels 10 ; hence, these agents have only a modest effect on fasting or night-time glucose levels or fasting insulin secretion. 10 However, the rapid increases in plasma concentrations of these short-acting RAs after their administration, together with a lack or slow development of tachyphylaxis, result in the substantial retardation of gastric emptying, thereby markedly lowering postprandial glucose excursions after meals prior to which they were administered (however, the correction of glucose excursions by short-acting GLP-1 RAs is less effective after meals prior to which ; position 8 in these molecules is equivalent to position 2 in exendin-4 derivatives. they were not administered). 10, 128 Effects on glucagon secretion and insulin secretion may also contribute. 130 Gastric emptying during meal-tolerance testing was significantly slowed by exenatide twice daily (no P value provided), whereas the effect was less pronounced with exenatide once weekly. 45 In addition, oncedaily lixisenatide administered before breakfast significantly reduced postprandial glucose during a morning test meal compared with liraglutide, also administered before breakfast, in patients with T2DM treated for 28 days. By contrast, liraglutide produced greater reductions in plasma glucose levels at all other times, including postprandial glucose after lunch and dinner, and fasting plasma glucose levels measured 24 hours after the last drug administration. 128 The differential effects of GLP-1 RAs on gastric emptying also affect the gastrointestinal tolerabilities of these agents (see Table 3 and Section 3.7).
| Long-acting GLP-1 RAs
Long-acting GLP-1 RAs produce continuous activation of the GLP-1 receptor, 10, 129 resulting in markedly reduced fasting glucose levels. This is reflected, for example, in the finding that reductions in glycaemia produced by dulaglutide are maintained throughout the weekly dosing cycle. Long-acting GLP-1 RAs also lower postprandial glucose excursions, 10, 36, 133 though not to the same extent as short-acting agents after meals prior to which short-acting drugs were administered. 10 However, long-acting GLP-1 RAs do reduce postprandial glycaemia to a greater degree than short-acting agents after meals prior to which short-acting drugs were not administered. 36, 128 Furthermore, long-acting GLP-1 RAs can be administered without consideration of meal times.
Long-acting compounds also have a much more marked effect on fasting glucose levels than short-acting GLP-1 RAs. 10 This, coupled with the effects on postprandial glucose that, as outlined above, they do maintain, explains why long acting GLP-1 RAs appear more "potent" than short-acting GLP- As an example, dulaglutide 1.5 and 0.75 mg once weekly reduced fasting serum glucose levels and premeal plasma glucose levels to a greater extent than exenatide twice daily (P < .001 for both doses and both measures vs exenatide) in a 26-week study in patients with T2DM receiving metformin and pioglitazone. 36 Interestingly, dulaglutide 1.5 mg reduced the mean of all self-monitored postprandial glucose levels more than exenatide twice daily (P < .047) and produced significantly greater postprandial glucose reduction after midday and the evening meal; the short-acting GLP-1 RA produced larger reductions in the mean of all 2-hour postprandial glucose excursions (P < .001) (Figure 2 
| Immunogenicity
As peptides, GLP-1 RAs can induce the production of antibodies.
Although the presence of these antibodies can increase the risk of local skin reactions, hypersensitivity or anaphylactic reactions and, in rare cases, neutralise the therapeutic effects of GLP-1 RAs; their clinical significance appears to be low in a majority of patients. 135 In a small number of patients exhibiting high antibody titres to exenatide once weekly, increasing antibody titre was associated with a significant (P < .0001) reduction in efficacy (vs low-titre antibodies). However, as higher-titre antibodies were not associated with lower individual glycaemic responses, the clinical relevance of these antibodies remains unclear. 135 For exenatide, the overall rate of antibody positivity was consistent across clinical trials (38% with low-titre and 6% with high-titre antibodies at 30 weeks in placebo-controlled trials). 3 
| Tolerability
Glucagon-like peptide-1 RAs also have different adverse event profiles, most notably with regard to the risk of gastrointestinal adverse events and injection-site reactions.
| Gastrointestinal events
The main adverse events of GLP-1 RA treatment are gastrointestinal in nature (ie, nausea, vomiting, and diarrhoea). Nausea and vomiting primarily result from dose-dependent delayed gastric emptying that is mediated by action on both central and peripheral receptors, 138, 139 whereas the mechanism of diarrhoea is less clear. 10 Nausea is reported with both short-and long-acting GLP-1 RAs but appears to attenuate more quickly with long-acting agents because of their lack of substantial effects on gastric emptying (Table 3) . 10 Across the trials summarised in Table 1 With both agents, injection-site reactions were more common in antidrug antibody-positive patients than in antibody-negative patients. 5, 8 Pooled data indicate that injection-site reactions were reported by about 5% of patients receiving exenatide twice daily in clinical trials; these events were usually mild and did not cause treatment withdrawal. 3 Injection-site reactions appear to be more common with exenatide once weekly than with exenatide twice daily. 45, 46 Such reactions (most commonly pruritus or erythema) are classified as a common adverse reaction (occurring with a frequency of between ≥1/100 and <1/10) in patients receiving exenatide once weekly. 4 Pooled 6-month data from controlled trials of exenatide once weekly
show that 16% of patients reported injection-site reactions that were usually mild and did not cause treatment withdrawal. 4 Small subcutaneous injection-site nodules, consistent with the known properties of the polymer microsphere formulation, occurred very frequently but were usually asymptomatic, did not cause treatment withdrawal and resolved over 4 to 8 weeks. 4 Across the trials of exenatide once weekly summarised in Table 1 , treatment discontinuations due to injection-site reactions of 0.2% to 1.7% have been reported.
Patients with antibodies to exenatide twice daily or once weekly tend to experience more injection-site reactions (eg, redness and itching) than those who remain antibody negative 3, 4, 50 ; however, most of these reactions were mild and transient and generally did not result in discontinuation of therapy. 135 Local injection-site reactions that occurred more frequently in antibody-positive patients included erythema, extravasation, haematoma, nodules, and pruritus. 50 About 2% of patients receiving liraglutide for periods over 26 weeks reported injection-site reactions (eg, injection-site rash and erythema) that were typically mild and led to discontinuations in less than 0.2% of patients. 6, 104 Injection-site reactions were observed in 1% to 2% of patients receiving semaglutide in clinical trials. 59, 65 In one head-to-head trial, semaglutide was associated with notably fewer injection-site reactions than exenatide once weekly (1.2% vs 22.0%).
65
Pooled data from the clinical trial programme showed that 2% of patients receiving dulaglutide reported injection-site reactions during treatment. 137 Potentially immune-mediated injection-site events (eg, rash and erythema) were reported by 0.5% of patients and were usually mild. 137 Similar percentages of patients (2% to 3%) experienced injection-site reactions in a recent head-to-head study of dulaglutide and semaglutide. 59 
| Use in special populations
The different routes of metabolism and elimination of the GLP-1 RAs (Table 4) have resulted in differences in dosing recommendations in patients with renal or hepatic impairment ( Liraglutide is not approved by European regulators for use in patients with severe hepatic impairment. 6 This recommendation appears to be based on the significantly lower (44%) exposure in this population rather than on clinical data. 6 European guidelines also state that caution should be used when using semaglutide in patients with severe hepatic impairment. 9 There are no US recommendations concerning the use of albiglutide, exenatide twice daily or once weekly, lixisenatide, or semaglutide in patients with hepatic impairment of any severity. 101, 102, 105, 109, 114 The US prescribing information states that dulaglutide 103 and liraglutide 104 should be used with caution in patients with any level of hepatic impairment.
| Dosing and need for titration
According to European prescribing information, all GLP-1 RAs can be administered with OADs and/or basal insulin. [3] [4] [5] [6] [7] [8] [9] Albiglutide, dulaglutide, liraglutide, and semaglutide can also be administered as monotherapy, and dulaglutide can be administered with prandial and basal insulin. [6] [7] [8] [9] In the United States, all GLP-1 RAs except dulaglutide 103 and semaglutide 105 have prescribing limitations for use in combination with insulin. This includes limitations for prandial (albiglutide, exenatide once weekly, exenatide twice daily, and liraglutide) and/short-acting insulins (lixisenatide). 101, 102, 104, 109, 114 For all GLP-1 RAs, the doses of concomitantly administered sulphonylureas or insulin may be reduced to minimise the risk of hypoglycaemia. [3] [4] [5] [6] [7] [8] [9] Self-monitoring of blood glucose is not required for GLP-1 RAs, although patients receiving sulphonylureas or insulin may need to do so to allow dose adjustment of these agents. [3] [4] [5] [6] [7] [8] [9] Titration requirements vary between GLP-1 RAs (Table 5 ). Some GLP-1 RAs (liraglutide, lixisenatide, and semaglutide) require titration to therapeutic dosages to attenuate gastrointestinal adverse effects. 142 The titration of semaglutide is particularly complex: after a starting dose of 0.25 mg once weekly for 4 weeks, the dose should be increased to 0.5 mg once weekly for at least another 4 weeks, following which the dose can be increased to 1 mg once weekly if required to further improve glycaemic control. 9 The starting dose of exenatide twice daily (5 mcg) should be continued for at least 4 weeks to improve tolerability, before being increased to 10 mcg twice daily if additional glycaemic control is needed. 3 Exenatide once weekly, available as a single-dosage strength, requires no titration. 4 The European label states that dulaglutide should be administered at a dosage of 0.75 mg once weekly if used as monotherapy and 1.5 mg once weekly if used as add-on therapy; an initial dose of 0.75 mg can be considered in potentially vulnerable patients (eg, those aged ≥75 years). 7 In the The initial dose should be administered for at least 1 month to improve tolerability.
c Most registration trials evaluated a 2-step titration regimen (10 mcg for 1 week, 15 mcg for 1 week then 20 mcg) [24] [25] [26] [27] ; other trials compared a 1-step with a 2-step regimen, 18, 22 whereas Asian studies used a 1-or 2-step regimen. Although all GLP-1 RAs are effective at lowering HbA 1c levels to varying degrees, with some agents also reducing body weight, other differences may also be considered when selecting the most appropriate GLP-1 RA for an individual patient.
| Differential effects on postprandial and fasting blood glucose
The pharmacodynamic characteristics of the various GLP-1 RAs available for the treatment of patients with T2DM, including differences in duration of action, affect their biological profiles, particularly their effects on postprandial and fasting blood glucose. In general, headto-head comparative studies show that long-acting GLP-1 RAs produce greater reductions in fasting blood glucose than the short-acting formulations by stimulating glucose-dependent insulin secretion and that they are able to improve all daily points of self-monitored blood glucose profiles, including both preprandial and postprandial levels.
All GLP-1 RAs reduce postprandial glucose levels and postprandial glucose excursions; however, short-acting agents produce greater reductions in postprandial glucose excursions (after meals prior to which they were administered) than long-acting formulations, probably by slowing gastric emptying. 10 
| Time to onset of action
Long-acting GLP-1 RAs appear to achieve maximal reductions in fasting plasma glucose levels more quickly than short-acting agents and may thus help patients achieve more rapid control of their diabetes. Among the long-acting agents, maximal reductions in fasting glucose levels are achieved more rapidly with albiglutide, administration. Nausea attenuates more slowly and lasts longer with short-acting agents than with long-acting GLP-1 RAs (Table 3) .
A review of the literature indicates that injection-site reactions are more common with albiglutide, 28 exenatide once weekly, 14 and, to a lesser extent, lixisenatide 24 and appear to be relatively uncommon with dulaglutide, 36, 42 liraglutide, 104 and semaglutide 59, 65 ; however, reporting of this adverse event in trials has generally been inconsistent. 144 In a recent preference study, twice as many participants were willing to take a medication with a dulaglutide-like profile than a similar medication with a liraglutide-like profile (77% vs 31%, respectively). 
| Use in special populations

